| Flunitrazepam | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
| Flunitrazepam | hsa00380 | Tryptophan metabolism | 4.14E-02 | 1 | Q16613 | AANAT | More | |
| Flunitrazepam | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
| Flunitrazepam | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Flunitrazepam | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | |
| Flunitrazepam | hsa03008 | Ribosome biogenesis in eukaryotes | 4.94E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | |
| Flunitrazepam | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | |
| Flunitrazepam | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | |
| Flunitrazepam | hsa03050 | Proteasome | 2.20E-03 | 2 | P55036, P28074 | PSMD4, PSMB5 | More | |
| Flunitrazepam | hsa04024 | cAMP signaling pathway | 3.37E-02 | 3 | P63092, P26678, P61586 | GNAS, PLN, RHOA | More | |
| Flunitrazepam | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | |
| Flunitrazepam | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | |
| Flunitrazepam | hsa04064 | NF-kappa B signaling pathway | 2.98E-04 | 13 | P10415, O00463, P14778, P19174, Q04759, Q9UDY8, Q16548, P06239, Q13315, P24522, P09341, P19875, Q06643 | BCL2, TRAF5, IL1R1, PLCG1, PRKCQ, MALT1, BCL2A1, LCK, ATM, GADD45A, CXCL1, CXCL2, LTB | More | |
| Flunitrazepam | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 5 | P21453, Q9H228, Q13362, Q9BX95, P10415 | S1PR1, EDG8, PPP2R5C, SGPP1, BCL2 | More | |
| Flunitrazepam | hsa04072 | Phospholipase D signaling pathway | 5.37E-03 | 8 | P42338, P61586, P43657, P25024, P25025, P19174, O14986, P63092 | PIK3CB, RHOA, P2RY5, CXCR1, CXCR2, PLCG1, PIP5K1B, GNAS | More | |
| Flunitrazepam | hsa04080 | Neuroactive ligand-receptor interaction | 1.00E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, ADRB2 | More | |
| Flunitrazepam | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | |
| Flunitrazepam | hsa04120 | Ubiquitin mediated proteolysis | 6.89E-03 | 5 | Q14145, Q13042, Q13191, Q15751, Q7Z6Z7 | KEAP1, CDC16, CBLB, HERC1, HUWE1 | More | |
| Flunitrazepam | hsa04137 | Mitophagy - animal | 2.52E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | |
| Flunitrazepam | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | |
| Flunitrazepam | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | |
| Flunitrazepam | hsa04145 | Phagosome | 4.48E-02 | 5 | Q15080, P05164, O60603, P35443, P13765 | NCF4, MPO, TLR2, THBS4, HLA-DOB | More | |
| Flunitrazepam | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | |
| Flunitrazepam | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | |
| Flunitrazepam | hsa04217 | Necroptosis | 4.42E-04 | 6 | P07900, P15104, P05141, P01584, P0C0S5, Q13557 | HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, CAMK2D | More | |
| Flunitrazepam | hsa04310 | Wnt signaling pathway | 4.17E-03 | 3 | P61586, P19784, P67870 | RHOA, CSNK2A2, CSNK2B | More | |
| Flunitrazepam | hsa04340 | Hedgehog signaling pathway | 3.09E-02 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | |
| Flunitrazepam | hsa04510 | Focal adhesion | 4.07E-02 | 3 | O14986, P61586, Q16363 | PIP5K1B, RHOA, LAMA4 | More | |
| Flunitrazepam | hsa04520 | Adherens junction | 1.38E-04 | 3 | P19784, P67870, P61586 | CSNK2A2, CSNK2B, RHOA | More | |
| Flunitrazepam | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
| Flunitrazepam | hsa04612 | Antigen processing and presentation | 4.48E-02 | 5 | P13765, P26715, P26717, Q13241, P01732 | HLA-DOB, KLRC1, KLRC2, KLRD1, CD8A | More | |
| Flunitrazepam | hsa04613 | Neutrophil extracellular trap formation | 4.93E-02 | 8 | O60603, P05164, P08246, Q9UM07, Q15080, P20160, P08311, P21730 | TLR2, MPO, ELA2, PADI4, NCF4, AZU1, CTSG, C5AR1 | More | |
| Flunitrazepam | hsa04621 | NOD-like receptor signaling pathway | 4.31E-02 | 4 | P01375, P59665, P59666, P12838 | TNF, DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
| Flunitrazepam | hsa04640 | Hematopoietic cell lineage | 2.18E-03 | 9 | P14778, P27930, P11215, P25063, P07766, P01732, P01730, P06127, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD4, CD5, CD7 | More | |
| Flunitrazepam | hsa04650 | Natural killer cell mediated cytotoxicity | 2.57E-04 | 10 | P19174, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, P26717, P26715 | PLCG1, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, KLRC2, KLRC1 | More | |
| Flunitrazepam | hsa04657 | IL-17 signaling pathway | 4.87E-02 | 2 | P07900, P01584 | HSP90AA1, IL1B | More | |
| Flunitrazepam | hsa04658 | Th1 and Th2 cell differentiation | 7.66E-07 | 12 | Q04759, P07766, P20963, P09693, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | |
| Flunitrazepam | hsa04659 | Th17 cell differentiation | 8.48E-05 | 11 | Q04759, P19174, P06239, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | |
| Flunitrazepam | hsa04660 | T cell receptor signaling pathway | 1.09E-04 | 12 | Q9UDY8, Q04759, P42338, P10747, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239 | MALT1, PRKCQ, PIK3CB, CD28, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK | More | |
| Flunitrazepam | hsa04713 | Circadian entrainment | 4.94E-02 | 2 | P62873, P63092 | GNB1, GNAS | More | |
| Flunitrazepam | hsa04723 | Retrograde endocannabinoid signaling | 4.94E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | |
| Flunitrazepam | hsa04724 | Glutamatergic synapse | 3.65E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | |
| Flunitrazepam | hsa04726 | Serotonergic synapse | 2.52E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | |
| Flunitrazepam | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | |
| Flunitrazepam | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | |
| Flunitrazepam | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | |
| Flunitrazepam | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | |
| Flunitrazepam | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.23E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | |
| Flunitrazepam | hsa04932 | Non-alcoholic fatty liver disease | 9.70E-03 | 4 | P18848, P01584, P13073, O15239 | ATF4, IL1B, COX4I1, NDUFA1 | More | |
| Flunitrazepam | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Flunitrazepam | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Flunitrazepam | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Flunitrazepam | hsa04972 | Pancreatic secretion | 3.65E-02 | 2 | P63092, P61586 | GNAS, RHOA | More | |
| Flunitrazepam | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | |
| Flunitrazepam | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | |
| Flunitrazepam | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | |
| Flunitrazepam | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | |
| Flunitrazepam | hsa05020 | Prion disease | 3.37E-03 | 7 | P13591, P01584, P11142, O15239, P13073, P18848, P05141 | NCAM1, IL1B, HSPA8, NDUFA1, COX4I1, ATF4, SLC25A5 | More | |
| Flunitrazepam | hsa05022 | Pathways of neurodegeneration - multiple diseases | 3.80E-02 | 6 | O15239, P13073, P18848, P05141, P01584, Q13557 | NDUFA1, COX4I1, ATF4, SLC25A5, IL1B, CAMK2D | More | |
| Flunitrazepam | hsa05032 | Morphine addiction | 9.04E-05 | 5 | P62873, P48169, P78334, P63092, P32298 | GNB1, GABRA4, GABRE, GNAS, GRK4 | More | |
| Flunitrazepam | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | |
| Flunitrazepam | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
| Flunitrazepam | hsa05134 | Legionellosis | 6.38E-04 | 6 | P01584, P11215, P68104, P11142, P09341, P19875 | IL1B, ITGAM, EEF1A1, HSPA8, CXCL1, CXCL2 | More | |
| Flunitrazepam | hsa05142 | Chagas disease | 2.26E-02 | 3 | P01375, P30679, P48023 | TNF, GNA15, FASLG | More | |
| Flunitrazepam | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | |
| Flunitrazepam | hsa05144 | Malaria | 3.09E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
| Flunitrazepam | hsa05146 | Amoebiasis | 2.21E-04 | 8 | P09341, P19875, P14778, P27930, P42338, P11215, P05089, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, PIK3CB, ITGAM, ARG1, ACTN1 | More | |
| Flunitrazepam | hsa05150 | Staphylococcus aureus infection | 1.83E-02 | 3 | P59665, P59666, P12838 | DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
| Flunitrazepam | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | |
| Flunitrazepam | hsa05163 | Human cytomegalovirus infection | 2.09E-02 | 4 | P62873, P61586, P63092, P61769 | GNB1, RHOA, GNAS, B2M | More | |
| Flunitrazepam | hsa05171 | Coronavirus disease - COVID-19 | 3.15E-04 | 9 | P01584, P62753, P25398, Q9UHA3, P36578, P32969, P18077, P62829, O14786 | IL1B, RPS6, RPS12, RSL24D1, RPL4, RPL9, RPL35A, RPL23, NRP1 | More | |
| Flunitrazepam | hsa05202 | Transcriptional misregulation in cancer | 2.90E-02 | 9 | Q12778, Q13315, P14780, Q16548, O15550, P05164, P08246, Q9C0K0, P24522 | FOXO1, ATM, MMP9, BCL2A1, UTX, MPO, ELA2, BCL11B, GADD45A | More | |
| Flunitrazepam | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 6.79E-04 | 9 | P42338, P19174, P07766, P20963, P09693, P06239, O60603, P10747, Q04759 | PIK3CB, PLCG1, CD3E, CD247, CD3G, LCK, TLR2, CD28, PRKCQ | More | |
| Flunitrazepam | hsa05321 | Inflammatory bowel disease | 1.17E-03 | 5 | O60603, P13765, Q14765, Q9UL17, P23771 | TLR2, HLA-DOB, STAT4, TBX21, GATA3 | More | |
| Flunitrazepam | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | |
| Flunitrazepam | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Flunitrazepam | hsa05332 | Graft-versus-host disease | 3.29E-04 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | |
| Flunitrazepam | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
| Flunitrazepam | hsa05415 | Diabetic cardiomyopathy | 2.87E-02 | 4 | P05141, O15239, P13073, Q13557 | SLC25A5, NDUFA1, COX4I1, CAMK2D | More | |
